查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1621752

血红素病市场机会、成长驱动因素、产业趋势分析与预测 2024 - 2032

Hemoglobinopathies Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2024 - 2032
出版日期: | 出版商: Global Market Insights Inc. | 英文 165 Pages | 商品交期: 2-3个工作天内

价格
简介目录

2023 年，全球血红蛋白病市场价值为 63 亿美元，在血红蛋白相关疾病的增加、遗传研究的发展和新的治疗发明的推动下，预计 2024 年至 2032 年的复合年增长率为 10.4%。血红蛋白疾病包括镰状细胞疾病 (SCD) 和地中海贫血等遗传性疾病，这些疾病会影响血红蛋白的结构和功能，而血红素是负责红血球中氧运输的蛋白质。该行业涵盖这些遗传性血液疾病的诊断、治疗和管理，提供旨在缓解症状和潜在治癒的药物、基因疗法、诊断测试和输血服务。市场依疾病类型分为地中海贫血和 SCD 等类别，其中地中海贫血进一步分为 α 型和 β 型。

2023年，SCD占据最大市场份额，价值33亿美元。 SCD 的治疗包括输血、疼痛管理和羟基脲，基因疗法和基于 CRISPR 的方法取得了有希望的进展。製药业和政府资助的支持正在促进创新治疗方案的开发。从治疗类型来看，市场分为输血、羟基脲、铁螯合疗法、骨髓移植等方法。

到 2023 年，输血将占据市场的 43.1%，并且仍然是一种重要的治疗方法，特别是在地中海贫血和 SCD 等疾病中。该疗法包括定期输注健康红血球，以缓解贫血、尽量减少併发症并改善患者的生活品质。输血治疗在发展中地区尤其重要，因为这些地区的先进治疗方案可能不太容易取得。从地区来看，到 2032 年，北美的复合年增长率预计将达到 10%，市场规模预计将达到 57 亿美元。

市场范围
开始年份 2023年
预测年份 2024-2032
起始值 63 亿美元
预测值 153 亿美元
复合年增长率 10.4%

美国血红蛋白病市场的成长得益于意识的提高、早期诊断以及对 SCD 和地中海贫血等疾病的先进治疗的采用。该地区强大的医疗基础设施促进了尖端诊断技术的快速整合，包括基因疗法和下一代定序。政府主导的倡议，例如新生儿筛检计划，也提高了早期检测率，显着提高了患者的治疗效果。随着对有效治疗的需求不断增长，以及政府和产业对先进疗法的投资增加，血红蛋白疾病市场必将大幅扩张。

这一增长与全球改善这些影响生命的血液疾病的诊断、治疗和整体管理的努力相一致。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

  • 产业生态系统分析
  • 产业影响力
    • 成长动力
      • 血红素病患病率增加
      • 诊断技术的进步
      • 新兴基因疗法与干细胞移植
    • 产业陷阱与挑战
      • 治疗费用高
      • 与治疗相关的副作用
  • 成长潜力分析
  • 监管环境
  • 管道分析
  • 未来市场趋势
  • 波特的分析
  • PESTEL分析

第 4 章：竞争格局

  • 介绍
  • 公司市占率分析
  • 公司矩阵分析
  • 主要市场参与者的竞争分析
  • 竞争定位矩阵
  • 战略仪表板

第 5 章：市场估计与预测：按疾病类型，2021 - 2032

  • 主要趋势
  • 地中海型贫血
    • α地中海贫血
    • β地中海型贫血
  • 镰形血球贫血症
  • 其他疾病类型

第 6 章：市场估计与预测：按处理方式，2021 - 2032 年

  • 主要趋势
  • 输血
  • 羟基脲
  • 铁螯合疗法
  • 骨髓移植
  • 其他治疗类型

第 7 章：市场估计与预测：按最终用途，2021 - 2032 年

  • 主要趋势
  • 医院
  • 专科诊所
  • 其他最终用户

第 8 章：市场估计与预测：按地区，2021 - 2032

  • 主要趋势
  • 北美洲
    • 我们
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 荷兰
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋

第 9 章：公司简介

  • bluebird bio
  • Bristol-Myers Squibb Company
  • CHIESI FARMACEUTICI
  • Emmaus Medical
  • Medunik USA
  • Novartis
  • Pfizer
  • Prolong Pharmaceuticals
  • Teva Pharmaceuticals Industries
  • Vertex Pharmaceuticals Incorporated
简介目录
Product Code: 11866

The Global Hemoglobinopathies Market was valued at USD 6.3 billion in 2023 and is anticipated to grow at a CAGR of 10.4% from 2024 to 2032, driven by a rise in hemoglobin associated diseases, developments in genetic research, and new therapeutic inventions. Hemoglobinopathies encompass genetic conditions such as sickle cell disease (SCD) and thalassemia that affect the structure and function of hemoglobin, the protein responsible for oxygen transport in red blood cells. This industry spans the diagnosis, treatment, and management of these inherited blood disorders, offering pharmaceuticals, gene therapies, diagnostic tests, and blood transfusion services aimed at both symptomatic relief and potential cures. The market is segmented by disease type into categories like thalassemia and SCD, with thalassemia further divided into alpha and beta forms.

In 2023, SCD accounted for the largest share of the market, valued at USD 3.3 billion. Treatments for SCD include blood transfusions, pain management, and hydroxyurea, with promising advancements in gene therapy and CRISPR-based approaches. Support from the pharmaceutical sector and government funding is fostering the development of innovative treatment options. In terms of treatment type, the market is divided into blood transfusion, hydroxyurea, iron chelation therapy, bone marrow transplant, and other methods.

Blood transfusions represented a notable 43.1% of the market in 2023 and remain a crucial treatment, especially in conditions like thalassemia and SCD. This therapy involves the regular transfusion of healthy red blood cells to alleviate anemia, minimize complications, and improve patients' quality of life. Blood transfusion therapy is particularly vital in developing regions, where advanced treatment options may be less accessible. Regionally, North America is poised to grow at 10% CAGR through 2032, with the market expected to reach USD 5.7 billion.

Market Scope
Start Year2023
Forecast Year2024-2032
Start Value$6.3 Billion
Forecast Value$15.3 Billion
CAGR10.4%

U.S. hemoglobinopathies market growth is supported by enhanced awareness, early diagnosis, and the adoption of advanced treatments for conditions like SCD and thalassemia. The region's strong healthcare infrastructure facilitates rapid integration of cutting-edge diagnostic technologies, including gene therapies and next-generation sequencing. Government-led initiatives, such as newborn screening programs, are also improving early detection rates, significantly boosting patient outcomes. With a growing demand for effective treatments and increased government and industry investment in advanced therapies, the hemoglobinopathies market is set for substantial expansion.

This growth aligns with global efforts to improve the diagnosis, treatment, and overall management of these life-impacting blood disorders.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates & calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Increasing prevalence of hemoglobinopathies
      • 3.2.1.2 Advancement in diagnostic technologies
      • 3.2.1.3 Emerging gene therapies and stem cell transplantation
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 High cost associated with treatment
      • 3.2.2.2 Side effects associated with treatment
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Pipeline analysis
  • 3.6 Future market trends
  • 3.7 Porter's analysis
  • 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company market share analysis
  • 4.3 Company matrix analysis
  • 4.4 Competitive analysis of major market players
  • 4.5 Competitive positioning matrix
  • 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Disease Type, 2021 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Thalassemia
    • 5.2.1 Alpha thalassemia
    • 5.2.2 Beta thalassemia
  • 5.3 Sickle cell disease
  • 5.4 Other disease types

Chapter 6 Market Estimates and Forecast, By Treatment, 2021 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Blood transfusion
  • 6.3 Hydroxyurea
  • 6.4 Iron chelation therapy
  • 6.5 Bone marrow transplant
  • 6.6 Other treatment types

Chapter 7 Market Estimates and Forecast, By End Use, 2021 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Hospitals
  • 7.3 Specialty clinics
  • 7.4 Other end users

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 France
    • 8.3.4 Spain
    • 8.3.5 Italy
    • 8.3.6 Netherlands
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 South Korea
  • 8.5 Latin America
    • 8.5.1 Brazil
    • 8.5.2 Mexico
    • 8.5.3 Argentina
  • 8.6 Middle East and Africa
    • 8.6.1 South Africa
    • 8.6.2 Saudi Arabia
    • 8.6.3 UAE

Chapter 9 Company Profiles

  • 9.1 bluebird bio
  • 9.2 Bristol-Myers Squibb Company
  • 9.3 CHIESI FARMACEUTICI
  • 9.4 Emmaus Medical
  • 9.5 Medunik USA
  • 9.6 Novartis
  • 9.7 Pfizer
  • 9.8 Prolong Pharmaceuticals
  • 9.9 Teva Pharmaceuticals Industries
  • 9.10 Vertex Pharmaceuticals Incorporated